Compare Sana Biotechnology Inc (SANA) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Twilio Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Twilio Inc trades at $195.94 (market cap $31.15B). The key difference: Twilio Inc is far larger — about 35.6× Sana Biotechnology Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | TWLO | |
|---|---|---|
Market Cap | $873.84M | $31.15B |
Sector | Health | Technology |
52-Week High | $5.92 | $236.64 |
52-Week Low | $2.68 | $92.44 |
Enterprise Value | $848.03M | $29.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twilio (TWLO) trades at $196.22, down 5.11% in the last session, as investors await Q2 2026 earnings on August 6. The stock shows a bullish technical signal with strong moving average support and oversold RSI conditions. Fundamentally, the company has delivered three consecutive earnings beats with revenue growth from $3.8B in 2022 to $5.1B in 2025, though profitability remains modest with a 1.96% net margin. Operating cash flow improved significantly to $1.0B in 2025, indicating stronger business execution.
The outlook remains positive with 77% analyst buy ratings and a $227.64 consensus price target representing 16% upside. Key opportunities include AI-powered communication growth and margin expansion, while risks center on high valuation multiples (P/E 311) and competitive pressures. The upcoming earnings report will be critical for validating the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
